Association of abnormal glucose tolerance with liver‐related disease and cardiovascular diseases in patients with chronic hepatitis C

Hepatitis C complicated by diabetes mellitus (DM) is considered a risk factor for the progression of fibrosis and development of hepatocellular carcinoma (HCC) and cardiovascular diseases. However, several studies may have lacked appropriate diagnosis of glucose intolerance. We aimed to examine the risk associated with abnormal glucose intolerance in the development of liver‐related diseases, including HCC and complications of liver cirrhosis, such as ascites, esophageal and gastric varices, and hepatic encephalopathy, and cardiovascular diseases in patients with hepatitis C accurately diagnosed with impaired glucose tolerance.

[1]  H. El‐Serag,et al.  Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection , 2022, The American journal of gastroenterology.

[2]  I. Ntalla,et al.  Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  M. Persico,et al.  Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[4]  G. Borgia,et al.  Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. , 2019, Reviews on recent clinical trials.

[5]  J. Miettola,et al.  Hepatitis C and risk of coronary atherosclerosis - A systematic review. , 2016, Public health.

[6]  G. Waris,et al.  Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. , 2015, World journal of gastroenterology.

[7]  Chung Y. Hsu,et al.  Increased Risk of Intracerebral Hemorrhage Among Patients With Hepatitis C Virus Infection , 2015, Medicine.

[8]  T. Maddox,et al.  Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. , 2015, World journal of diabetes.

[9]  E. Schiff,et al.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. , 2015, Gastroenterology.

[10]  Takanori Ito,et al.  Risk factors of hepatocellular carcinoma development in non‐cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection , 2015, Journal of gastroenterology and hepatology.

[11]  J. Mehta,et al.  Impact of Hepatitis C Seropositivity on the Risk of Coronary Heart Disease Events , 2014, The American journal of cardiology.

[12]  N. Enomoto,et al.  α‐fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C , 2013, Hepatology.

[13]  M. Imamura,et al.  Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis , 2013, Journal of Gastroenterology.

[14]  Yoshiyuki Suzuki,et al.  Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C , 2013, Hepatology.

[15]  A. Lonardo,et al.  Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. , 2012, Atherosclerosis.

[16]  Hirokazu Takahashi,et al.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011, Journal of gastroenterology.

[17]  T. Sasazuki,et al.  Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. , 2010, Journal of diabetes and its complications.

[18]  N. Enomoto,et al.  Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection , 2010, Hepatology.

[19]  Sheng-Nan Lu,et al.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. , 2010, World journal of gastroenterology.

[20]  T. Ogihara,et al.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) , 2009, Hypertension Research.

[21]  M. Shlipak,et al.  Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. , 2009, Journal of cardiac failure.

[22]  M. Budoff,et al.  Hepatitis C virus infection and the risk of coronary disease. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[24]  Zongyi Hu,et al.  Structural proteins of Hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. , 2005, The Journal of general virology.

[25]  F. Bianchi,et al.  Sirolimus eluting stent aborted recurrent distal left main in-stent restenosis involving bifurcation , 2004, Heart.

[26]  K. Koike,et al.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.

[27]  H. Knobler,et al.  Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. , 2000, Mayo Clinic proceedings.

[28]  C. Mussini,et al.  Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis , 1990, La Ricerca in clinica e in laboratorio.

[29]  K. Nanjo,et al.  Hemoglobin A1 in cirrhosis of the liver. , 1989, Diabetes research.

[30]  A. Varriale,et al.  Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. , 1988, Diabetes research.

[31]  A. Craxì,et al.  Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. , 2016, Gastroenterology.

[32]  K. Shimamoto.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 (JSH2014) , 2014 .

[33]  Hirokazu TakahashiToshihiko,et al.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C , 2011 .

[34]  F. Irie,et al.  Relationship between obesity and incident diabetes in middle-aged and older Japanese adults: the Ibaraki Prefectural Health Study. , 2010, Mayo Clinic proceedings.

[35]  Shohei Matsuzaki,et al.  Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background , 2003, Journal of Gastroenterology.

[36]  C. Palmer,et al.  Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. , 1994, Journal of hepatology.